Products from BPS Bioscience require a minimum order value above 400€
Applications: Useful for screening and validating antibodies against CD22 and different CD22 CAR-T for immunotherapy research and drug discovery.
Background: CD22, also known as Siglec-2, is expressed on the membrane of B-cells. It is reported to act as an inhibitory co-receptor of the B-cell receptor to control the body's B-cell response. In 2017 the FDA approved inotuzumab ozogamicin (Besponsa), an antibody-drug conjugate targeting CD22, for patients with B-cell acute lymphoblastic leukemia (ALL). Additional therapies targeting CD22 are under evaluation.
Description: Recombinant clonal stable CHO cell line constitutively expressing full length human CD22 protein (Genbank #NM_001771) and the firefly luciferase. Surface expression of CD22 was confirmed by flow cytometry.
Host Cell Line: CHO
Mycoplasma Testing: This cell line has been screened using the MycoAlert™ Mycoplasma Detection Kit (Lonza, #LT07-118) to confirm the absence of Mycoplasma contamination. MycoAlert Assay Control Set (Lonza, #LT07-518) was used as a positive control.
Storage Stability: Store in liquid nitrogen immediately upon receipt.
Supplied As: Each vial contains ~ 2 x 10^6 cells in 1 ml of 10% DMSO in FBS.
Warnings: Avoid multiple freeze/thaw cycles.
Biosafety Level: BSL-1
References: 1. Poe J, et al. CD22 and Siglec-G in B cell function and tolerance. Trends Immunol. 2012 Aug; 33(8):413-420.2. Dorner T, et al. The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus. Autoimmunity Reviews. 2015 14:1079-1086.3. Wei G., et al. Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia. Journal of Hematology and Oncology. 2017 10:1-13.
English
Deutsch
